Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Basanta, Maria ^a   Ibrahim, Baharudin ^a   Dockry, Rachel ^a   Douce, David ^b   Morris, Mike ^b   Singh, Dave ^a   Woodcock, Ashley ^a   Fowler, Stephen J ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WATERS CORPORATION   (United States)

^c LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biomarkers; Breath tests; Chronic obstructive pulmonary disease; Metabolomics

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; STEROID; VOLATILE ORGANIC COMPOUND;

AGED; ARTICLE; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; EOSINOPHILIA; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; PATIENT CODING; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SPUTUM ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY; CHEMISTRY; CROSS-SECTIONAL STUDY; EXHALATION; MASS FRAGMENTOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; SPUTUM;

AGED; CROSS-SECTIONAL STUDIES; EXHALATION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; VOLATILE ORGANIC COMPOUNDS;

EID: 84865226828     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-72     Document Type: Article

References (26)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555. 10.1164/rccm.200703-456SO, 17507545.
2. Chronic obstructive pulmonary disease National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004, 59(Suppl 1):1-232. 1766028, 15041752, Chronic obstructive pulmonary disease.
3. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity, Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996, 153(5):1530-1535.
4. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57(10):847-852. 10.1136/thorax.57.10.847, 1746193, 12324669.
5. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005, 60(3):193-198. 10.1136/thx.2004.032516, 1747331, 15741434.
6. Vestbo J, Rennard S. Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed-Urgently. Am J Respir Crit Care Med 2010, 182(7):863-864. 10.1164/rccm.201004-0602ED, 20884938.
7. Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen EJ, Wouters EF, Van Schooten FJ. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 2010, 104(4):557-563. 10.1016/j.rmed.2009.10.018, 19906520.
8. Basanta M, Jarvis RM, Xu Y, Blackburn G, Tal-Singer R, Woodcock A, Singh D, Goodacre R, Thomas CL, Fowler SJ. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst 2010, 135(2):315-320. 10.1039/b916374c, 20098764.
9. Fens N, de Nijs SB, Peters S, Dekker T, Knobel HH, Vink TJ, Willard NP, Zwinderman AH, Krouwels FH, Janssen HG, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J
10. Motta A, Paris D, Melck D, de Laurentiis G, Maniscalco M, Sofia M, Montuschi P. Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects. Eur Respir J 2012, 39(2):498-500. 10.1183/09031936.00036411, 22298616.
11. Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax 66(9):804-809.
12. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008, 31(4):869-873. 10.1183/09031936.00111707, 18216052.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338. 10.1183/09031936.05.00034805, 16055882.
14. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996, 9(6):1174-1180. 10.1183/09031936.96.09061174, 8804934.
15. Basanta M, Ibrahim B, Douce D, Morris M, Woodcock A, Fowler SJ. Methodology validation, intra-subject reproducibility and stability of exhaled volatile organic compounds. J Breath Res 6(2):026002.
16. Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen E, Wouters EF, Van Schooten FJ. Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 861(1):101-107. 10.1016/j.jchromb.2007.11.008, 18055279.
17. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010, 125(5):1028-1036. e1013, 10.1016/j.jaci.2010.02.008, 2878277, 20398920.
18. Izquierdo-García JL, Puerto-Nevado L, Peces-Barba G, Pérez-Rial S, Heili S, Villa P, Castejón D, González-Mangado N, Ruiz-Cabello N. A metabonomic approach to evaluate COPD in a model of cigarette smoke exposure in mice. Metabolomics 2010, 6(4):564-573.
19. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark 2007, 3(2):95-109.
20. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39(4):561-577.
21. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans 2009, 037(4):819-823.
22. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 11:77.
23. Ashley DL, Bonin MA, Cardinali FL, McCraw JM, Wooten JV. Blood concentrations of volatile organic compounds in a nonoccupationally exposed US population and in groups with suspected exposure. Clin Chem 1994, 40(7 Pt 2):1401-1404.
24. Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo RN. Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Sci Appl 1999, 729(1-2):75-88.
25. Facchinetti F, Amadei F, Geppetti P, Tarantini F, Di Serio C, Dragotto A, Gigli PM, Catinella S, Civelli M, Patacchini R. Alpha, beta-unsaturated aldehydes in cigarette smoke release inflammatory mediators from human macrophages. Am J Respir Cell Mol Biol 2007, 37(5):617-623. 10.1165/rcmb.2007-0130OC, 17600310.
26. Montuschi P. LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(13):1272-80. 10.1016/j.jchromb.2009.01.036, 19233745.